Secunderabad Chronicle

Metastatic Triple-Negative Breast Cancer Epidemiology Forecast Report 2030 | Metastatic Triple-Negative Breast Cancer Epidemiology Analysis 2030 | DelveInsight

 Breaking News
  • No posts were found

Metastatic Triple-Negative Breast Cancer Epidemiology Forecast Report 2030 | Metastatic Triple-Negative Breast Cancer Epidemiology Analysis 2030 | DelveInsight

September 10
14:08 2021
Metastatic Triple-Negative Breast Cancer Epidemiology Forecast Report 2030 | Metastatic Triple-Negative Breast Cancer Epidemiology Analysis 2030 | DelveInsight
DelveInsight Business Research LLP
DelveInsight’s “Metastatic triple-negative breast cancer (mTNBC) – Epidemiology Forecast to 2030” report delivers an in-depth understanding of the disease, historical and forecasted Metastatic triple-negative breast cancer (mTNBC) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

DelveInsight launched a new report on Metastatic Triple-Negative Breast Cancer Epidemiology Forecast, 2030.

Metastatic Triple-Negative Breast Cancer (mTNBC) is defined as the metastatic tumor where the estrogen and progesterone (ER/PR)  are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers. 

DelveInsight’s Metastatic Triple-Negative Breast Cancer Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Metastatic Triple-Negative Breast Cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Some of the key highlights from the Metastatic Triple-Negative Breast Cancer Epidemiology Report:

  • DelveInsight has also estimated the Sub-type specific cases of TNBC, which are  ER-, PR- and HER2-. In the United States, there were 4,793 cases of HER2-TNBC, followed by PR- and ER- subtypes.

  • Out of the total cases of Triple-Negative Breast Cancer, 8,466 cases were in the advanced stage in the US in 2017. 

  • Amongst the EU-5 countries (Germany, France, the United Kingdom, Spain, and Italy), Germany had the highest diagnosed incidence of TNBC and accounted for 12,516 cases followed by France and Italy in the year 2017.

Visit for more @ Metastatic Triple-Negative Breast Cancer Epidemiology Insights

Scope of the Metastatic Triple-Negative Breast Cancer Epidemiology report:

  1. The Metastatic Triple-Negative Breast Cancer report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns

  2. The Metastatic Triple-Negative Breast Cancer Epidemiology Report and Model provide an overview of the risk factors and global trends of Metastatic Triple-Negative Breast Cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)

  3. The report provides insight into the historical and forecasted patient pool of Metastatic Triple-Negative Breast Cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan

  4. The report helps to recognize the growth opportunities in the 7MM concerning the patient population

  5. The report assesses the disease risk and burden and highlights the unmet needs of Metastatic Triple-Negative Breast Cancer

  6. The report provides the segmentation of the Metastatic Triple-Negative Breast Cancer epidemiology

Table of Contents:

1. Key Insights

2. Executive Summary of Metastatic Triple-Negative Breast Cancer

3. Metastatic Triple-Negative Breast Cancer Epidemiology Overview at a Glance

4. Metastatic Triple-Negative Breast Cancer: Disease Background and Overview

5. Epidemiology and Patient Population

6. Case Reports

7. Country Wise-Epidemiology of Metastatic Triple-Negative Breast Cancer 

8. Appendix

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

Related Reports:

Metastatic Triple-Negative Breast Cancer Market

DelveInsight’s ‘Metastatic Triple-Negative Breast Cancer-Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom), 

Metastatic Triple-Negative Breast Cancer Pipeline 

“Metastatic Triple-Negative Breast Cancer Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Metastatic Triple-Negative Breast Cancer market. A detailed picture of the Metastatic Triple-Negative Breast Cancer pipeline landscape is provided, which includes the disease overview and Metastatic Triple-Negative Breast Cancer treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles